Diamond Therapeutics Inc. is a private, Toronto-based company with a mission to develop new and better drugs for mental health conditions by unlocking the promise of psychedelic compounds.
The company is focused on developing and commercializing sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the global mental health crisis.